Inappropriate antidiuretic hormone secretion adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,018 adverse event reports that record the MedDRA preferred term Inappropriate antidiuretic hormone secretion. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 904 reports in the 12 months to June 2026 and 571 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 656 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 904 (0.1%) record this term. Reports for patients 75 and over were 30.4% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 150 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Inappropriate antidiuretic hormone secretion name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	78
Acetaminophen		64
Aldactone	Aldosterone antagonist	42
Alprazolam	Benzodiazepine	59
Amiodarone		35
Amisulpride	Dopamine-2 receptor antagonist	31
Amitriptyline		39
Amitriptyline hydrochloride	Tricyclic antidepressant	25
Amlodipine	Calcium channel blocker	45
Aprepitant	Substance P/Neurokinin-1 receptor antagonist	28
Aripiprazole	Atypical antipsychotic	96
Asparaginase		38
Avastin	Vascular endothelial growth factor inhibitor	31
Bactrim	Dihydrofolate reductase inhibitor antibacterial	32
Bendroflumethiazide		37
Bevacizumab	Vascular endothelial growth factor inhibitor	47
Bisoprolol	beta-Adrenergic blocker	43
Bortezomib	Proteasome inhibitor	55
Brintellix		28
Bromazepam		26
Bupropion	Aminoketone	43
Busulfan	Alkylating drug	114
Candesartan	Angiotensin 2 receptor blocker	54
Capecitabine	Nucleoside metabolic inhibitor	25
Carbamazepine	Mood stabilizer	150
Carboplatin	Platinum-based drug	274
Ciprofloxacin	Fluoroquinolone antibacterial	128
Cisplatin	Platinum-based drug	241
Citalopram	Serotonin reuptake inhibitor	232
Citalopram hydrobromide	Serotonin reuptake inhibitor	80
Clomipramine		27
Clonazepam	Benzodiazepine	59
Clozapine	Atypical antipsychotic	42
Cyclophosphamide	Alkylating drug	311
Cyclosporine	Calcineurin inhibitor immunosuppressant	131
Cymbalta		122
Cytarabine	Nucleoside metabolic inhibitor	91
Daptomycin		25
Daunorubicin		39
Depakote	Anti-epileptic agent	34
Deroxat		29
Desmopressin		27
Dexamethasone	Corticosteroid	172
Diazepam	Benzodiazepine	62
Docetaxel	Microtubule inhibitor	37
Doxorubicin	Anthracycline topoisomerase inhibitor	64
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	40
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	201
Duloxetine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	93
Enalapril	Angiotensin converting enzyme inhibitor	66
Enalapril maleate	Angiotensin converting enzyme inhibitor	31
Escitalopram	Serotonin reuptake inhibitor	254
Escitalopram oxalate	Serotonin reuptake inhibitor	37
Esomeprazole	Proton pump inhibitor	159
Etoposide	Topoisomerase inhibitor	137
Fludarabine	Nucleoside metabolic inhibitor	109
Fluorouracil	Nucleoside metabolic inhibitor	77
Fluoxetine	Serotonin reuptake inhibitor	133
Fluoxetine hydrochloride	Serotonin reuptake inhibitor	35
Furosemide	Loop diuretic	160
Gabapentin	Anti-epileptic agent	96
Haldol		30
Haloperidol	Typical antipsychotic	82
Hydrochlorothiazide	Thiazide diuretic	246
Hydrochlorothiazide Irbesartan		29
Hydrocortisone	Corticosteroid	30
Ibuprofen	Nonsteroidal anti-inflammatory drug	65
Imatinib	Kinase inhibitor	28
Indapamide	Thiazide-like diuretic	145
Inexium		49
Ipilimumab	CTLA-4-directed blocking antibody	37
Irbesartan	Angiotensin 2 receptor blocker	48
Kardegic		25
Keppra		34
Keytruda	Programmed death Receptor-1 blocking antibody	103
Lamotrigine	Anti-epileptic agent	106
Lansoprazole	Proton pump inhibitor	208
Lenalidomide	Thalidomide analog	26
Levetiracetam		82
Levofloxacin	Fluoroquinolone antibacterial	49
Lexapro	Serotonin reuptake inhibitor	34
Linezolid	Oxazolidinone antibacterial	65
Lisinopril	Angiotensin converting enzyme inhibitor	86
Lorazepam	Benzodiazepine	97
Lyrica		50
Melphalan	Alkylating drug	39
Metformin	Biguanide	51
Methotrexate	Folate analog metabolic inhibitor	156
Methylprednisolone	Corticosteroid	71
Metoclopramide	Dopamine-2 receptor antagonist	25
Mirtazapine		317
Mycophenolate mofetil	Antimetabolite immunosuppressant	158
Nexium	Proton pump inhibitor	44
Nivolumab	Programmed death Receptor-1 blocking antibody	70
Olanzapine	Atypical antipsychotic	218
Omeprazole	Proton pump inhibitor	384
Ondansetron	Serotonin-3 receptor antagonist	47
Opdivo	Programmed death Receptor-1 blocking antibody	65
Oxaliplatin	Platinum-based drug	69
Oxazepam	Benzodiazepine	42
Oxcarbazepine	Anti-epileptic agent	121
Paclitaxel	Microtubule inhibitor	89
Paliperidone	Atypical antipsychotic	25
Pantoprazole	Proton pump inhibitor	287
Paracetamol		27
Paroxetine	Serotonin reuptake inhibitor	121
Paroxetine hydrochloride	Serotonin reuptake inhibitor	47
Paxil	Serotonin reuptake inhibitor	134
Pembrolizumab	Programmed death Receptor-1 blocking antibody	28
Perindopril		83
Posaconazole	Azole antifungal	39
Pramipexole	Nonergot dopamine agonist	34
Prednisolone	Corticosteroid	95
Prednisone	Corticosteroid	116
Pregabalin		84
Quetiapine	Atypical antipsychotic	151
Quetiapine fumarate	Atypical antipsychotic	44
Ramipril	Angiotensin converting enzyme inhibitor	145
Revlimid	Thalidomide analog	32
Risperdal	Atypical antipsychotic	61
Risperidone	Atypical antipsychotic	133
Rituximab	CD20-directed cytolytic antibody	58
Seroquel	Atypical antipsychotic	37
Sertraline	Serotonin reuptake inhibitor	264
Sertraline hydrochloride	Serotonin reuptake inhibitor	65
Spironolactone	Aldosterone antagonist	96
Tacrolimus	Calcineurin inhibitor immunosuppressant	168
Taxotere		30
Tegretol	Mood stabilizer	130
Thiotepa	Alkylating drug	125
Torsemide	Loop diuretic	30
Tramadol		130
Tramadol hcl	Opioid agonist	41
Tramadol hydrochloride	Opioid agonist	40
Trazodone		49
Trileptal	Anti-epileptic agent	76
Trintellix		46
Valproate sodium	Anti-epileptic agent	38
Valproic acid	Anti-epileptic agent	49
Velcade	Proteasome inhibitor	100
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	142
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	71
Vfend	Azole antifungal	28
Vincristine		146
Vincristine sulfate	Vinca alkaloid	107
Voriconazole	Azole antifungal	56
Yervoy	CTLA-4-directed blocking antibody	28
Zoloft	Serotonin reuptake inhibitor	50
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	48
Zyprexa	Atypical antipsychotic	63

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 58 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Inappropriate antidiuretic hormone secretion name, in order of name
Class	Reports with this term
Aldosterone antagonist	138
Alkylating drug	642
alpha-Adrenergic blocker	28
Aminoketone	52
Angiotensin 2 receptor blocker	225
Angiotensin converting enzyme inhibitor	345
Anthracycline topoisomerase inhibitor	114
Anti-epileptic agent	585
Antimetabolite immunosuppressant	184
Antimycobacterial	27
Atypical antipsychotic	990
Azole antifungal	177
Benzodiazepine	377
beta-Adrenergic blocker	112
Biguanide	65
Bisphosphonate	39
Calcineurin inhibitor immunosuppressant	324
Calcium channel blocker	50
CD20-directed cytolytic antibody	66
Corticosteroid	525
CTLA-4-directed blocking antibody	68
Dihydrofolate reductase inhibitor antibacterial	86
Dopamine-2 receptor antagonist	56
Fluoroquinolone antibacterial	183
Folate analog metabolic inhibitor	189
gamma-Aminobutyric acid A receptor positive modulator	55
Herpes simplex virus nucleoside analog DNA polymerase inhibitor	46
HMG-CoA reductase inhibitor	41
Kinase inhibitor	192
Loop diuretic	213
Microtubule inhibitor	135
Mood stabilizer	284
N-methyl-D-aspartate receptor antagonist	39
Nonergot dopamine agonist	55
Nonsteroidal anti-inflammatory drug	138
Nucleoside metabolic inhibitor	375
Opioid agonist	139
Osmotic laxative	35
Oxazolidinone antibacterial	67
P2Y12 platelet inhibitor	27
Phenothiazine	32
Platinum-based drug	584
Programmed death Ligand-1 blocker	27
Programmed death Receptor-1 blocking antibody	314
Proteasome inhibitor	171
Proton pump inhibitor	1,160
Serotonin and norepinephrine reuptake inhibitor	554
Serotonin reuptake inhibitor	1,563
Serotonin-3 receptor antagonist	51
Substance P/Neurokinin-1 receptor antagonist	52
Thalidomide analog	58
Thiazide diuretic	261
Thiazide-like diuretic	165
Topoisomerase inhibitor	140
Tricyclic antidepressant	66
Typical antipsychotic	84
Vascular endothelial growth factor inhibitor	78
Vinca alkaloid	109

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Inappropriate antidiuretic hormone secretion, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Inappropriate antidiuretic hormone secretion
Age	Reports	Share
Under 2	24	0.2%
2 to 11	211	2.1%
12 to 17	162	1.6%
18 to 44	724	7.2%
45 to 64	1,870	18.7%
65 to 74	2,187	21.8%
75 and over	3,044	30.4%
Age not given	1,796	17.9%

Sex of the patient in the reports that record Inappropriate antidiuretic hormone secretion
Sex	Reports	Share
Female	5,135	51.3%
Male	3,846	38.4%
Unknown or not given	1,037	10.4%

Age and sex are as the report gives them. 19.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Inappropriate antidiuretic hormone secretion: adverse event reports that record this term. https://reportedreactions.com/reaction/inappropriate-antidiuretic-hormone-secretion/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Inappropriate antidiuretic hormone secretion mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page